FN Plzeň

Prof. Dr. FN Plzeň

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2005 in Journal of Clinical Gastroenterology
Verified
Journal Article
Closed access
Josef SýkoraJosef Sýkora
Josef Sýkora
KVKristýna Valecková
Kristýna Valecková
JAJana Amlerová
Jana Amlerová
KSKonrad Siala
Konrad Siala
PDPetr Dedek
Petr Dedek
JSJan Schwarz
Jan Schwarz
To determine the efficacy of triple therapy supplemented with a specially designed fermented milk product containing specific probiotic Lactobacillus casei (L. casei) DN-114 001 strain on Helicobacter pylori eradication in children. Lactobacillus species possess in vitro activity against H. pylori. There are no consistent data on the impact of eradication therapy supplemented with probiotics on H. pylori cure rates in childhood in vivo. Multicenter, prospective, randomized, double-blind controlled study. Eighty-six symptomatic H. pylori-positive children were randomized either to receive the control treatment of omeprazole, amoxicillin, and clarithromycin (OAC) for 7 days or the test treatment of omeprazole, amoxicillin, and clarithromycin for 7 days supplemented with fermented milk (Actimel) containing L. casei DN-114 001 (OAC-LC), for 14 days. H. pylori status was assessed at 4 weeks following therapy using two noninvasive tests. Intention-to-treat (ITT) based eradication rates for the OAC-LC group were 84.6% (95% CI, 71.2%-95.5%), and 91.6% (95% CI, 76.9%-98.2%) by per-protocol (PP) analysis. Eradication in the OAC group was 57.5% (95% CI, 42.2%-72.3%) in the ITT set and 61.3% (95% CI, 44.4%-75.0%) in the PP group. Eradication success was higher in the OAC-LC group compared with the OAC group in both ITT (P=0.0045) and PP analysis (P=0.0019). Primary resistance for clarithromycin could be determined in 21.2%. Side effects were infrequent. Drug compliance was good throughout the study. Supplementation with fermented milk, containing live special probiotic L. casei DN-114 001, confers an enhanced therapeutic benefit on H. pylori eradication in children with gastritis on triple therapy.

1 May 2014 in Vaccine
Verified
Journal Article
Open access
RPRoman Prymula
Roman Prymula
FPFN Plzeň
FN Plzeň
MTMagali Traskine
Magali Traskine
JRJens U. Rüggeberg
Jens U. Rüggeberg
DBDorota Borys
Dorota Borys
To provide broader protection against pneumococcal disease, new vaccines containing conserved Streptococcus pneumoniae proteins are being developed. This study assessed the safety, reactogenicity and immunogenicity of four formulations containing pneumococcal proteins pneumolysin toxoid (dPly) and histidine triad protein (PhtD) in toddlers. In this phase II, multicenter, observer-blind study (www.clinicaltrials.gov: NCT00985751) conducted in the Czech Republic, toddlers (12-23 months) were randomized (1:1:1:1:1) to receive one of four investigational vaccine formulations (10 or 30μg each of dPly and PhtD, alone or in combination with polysaccharide conjugates from the pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine [PHiD-CV]), or the licensed PHiD-CV, in a 2-dose primary series plus booster at study months 0, 2 and 6. Solicited local and general symptoms were recorded within seven days post-vaccination, unsolicited symptoms within 31 days post-vaccination, and serious adverse events (SAEs) during the entire study period. Antibody concentrations against the vaccine components were measured pre-vaccination, one month post-dose 2, pre- and one month post-booster. 257 toddlers were enrolled and vaccinated. Percentages of solicited local and general symptoms following the different investigational formulations were generally within the same ranges as for PHiD-CV. After each dose, grade 3 fever (>40.0°C, rectal measurement) was reported for maximum one toddler in each group with no differences between investigational formulations and PHiD-CV during primary vaccination. 23 SAEs were reported for 17 toddlers, with distribution balanced between all groups except the group receiving 30 μg dPly/PhtD with PHiD-CV-conjugates (no SAEs reported). None of the SAEs were considered to be vaccine-related. For all pneumococcal protein-containing formulations, anti-PhtD and anti-Ply antibody geometric mean concentrations increased from pre-vaccination to post-dose 2 and from pre- to post-booster vaccination. All investigational vaccine formulations were well-tolerated and immunogenic when administered to toddlers as a 2-dose primary vaccination followed by a booster dose.

23 July 2009 in Helicobacter
Verified
Journal Article
Closed access
PDF file
Josef SýkoraJosef Sýkora
Josef Sýkora
KSKonrad Siala
Konrad Siala
JVJana Varvařovská
Jana Varvařovská
FPFN Plzeň
FN Plzeň
RPRenáta Pomahačová
Renáta Pomahačová
MHMichal Huml
Michal Huml

1 May 2006 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
Josef SýkoraJosef Sýkora
Josef Sýkora
IŠIvan Šubrt
Ivan Šubrt
PDPetr Dìdek
Petr Dìdek
KSKonrad Siala
Konrad Siala
JSJan Schwarz
Jan Schwarz
FSFrantišek Stožický
František Stožický

15 September 2010 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
OGon behalf of the SPRIK Rotavirus Study Group
on behalf of the SPRIK Rotavirus Study Group
JDJAVIER DIEZ DOMINGO
JAVIER DIEZ DOMINGO
JBJose-Maria Baldo
Jose-Maria Baldo
MPMarian Patrzalek
Marian Patrzalek
FPFN Plzeň
FN Plzeň
NMNadia Meyer
Nadia Meyer

17 March 2016 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
MCMehmet Ceyhan
Mehmet Ceyhan
RDRon Dagan
Ron Dagan
ASAbdullah Sayiner
Abdullah Sayiner
LCLiudmyla Chernyshova
Liudmyla Chernyshova
Ener Cagri DinleyiciEner Cagri Dinleyici
Ener Cagri Dinleyici
LYLyazzat Yeraliyeva
Lyazzat Yeraliyeva
Pneumococcal infection is a major cause of morbidity and mortality worldwide. The burden of disease associated with S. pneumoniae is largely preventable through routine vaccination. Pneumococcal conjugate vaccines (e.g. PCV7, PCV13) provide protection from invasive pneumococcal disease as well as non-invasive infection (pneumonia, acute otitis media), and decrease vaccine-type nasopharyngeal colonisation, thus reducing transmission to unvaccinated individuals. PCVs have also been shown to reduce the incidence of antibiotic-resistant pneumococcal disease. Surveillance for pneumococcal disease is important to understand local epidemiology, serotype distribution and antibiotic resistance rates. Surveillance systems also help to inform policy development, including vaccine recommendations, and monitor the impact of pneumococcal vaccination. National pneumococcal surveillance systems exist in a number of countries in Central and Eastern Europe (such as Croatia, Czech Republic, Hungary, Poland, Romania and Slovakia), and some have introduced PCVs (Czech Republic, Hungary, Kazakhstan, Russia, Slovakia and Turkey). Those countries without established programs (such as Kazakhstan, Russia and Ukraine) may be able to learn from the experiences of those with national surveillance systems. The serotype distributions and impact of PCV13 on pediatric pneumococcal diseases are relatively similar in different parts of the world, suggesting that approaches to vaccination used elsewhere are also likely to be effective in Central and Eastern Europe. This article briefly reviews the epidemiology of pneumococcal disease, presents the latest surveillance data from Central and Eastern Europe, and discusses any similarities and differences in these data as well the potential implications for vaccination policies in the region.